Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Results

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 25, 2023 11:09am

171 Views

Post# 35360251

RE:Results

Deal flow should be healthy - a lot of struggling small pharma companies out there.
Question is ... does GUD find the right deals at the right prices?
Best opportunities in a long time (I would assume).

Growth with Samira/Goodman always plateaus and stalls - gets a shot in the arm - moves forward again.
That is the nature of their business - all in how they manage it.

$170 in cash.
They didn't renew the shelf prospectus but I'd say they'll hold off a bit - that's really to take advantage of ATE on P3 plans (IMO). Maybe closer to year end - or - early 2024 to renew ?

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload